{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-223726","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2024-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.091367+00:00","generated_at":"2026-05-31T02:16:30.344046+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acadia CEO Stephen R. Davis terminated Sept 23; Catherine Owen Adams appointed","bullets":["Stephen R. Davis involuntarily terminated without cause as President and CEO effective Sept 23, 2024; resigns from board.","Davis receives severance: 1.5x base+target bonus, pro-rata 2024 bonus, 12 months accelerated equity, 18 months COBRA.","Catherine Owen Adams appointed CEO and director effective Sept 23; previously SVP and GM U.S. at BMS overseeing $20B business.","Adams compensation: $900k base salary, 80% target bonus, $500k sign-on, plus equity awards of $3.25M in options and $3.25M in PSUs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-223726","json":"https://secwatch.observer/filing/0001193125-24-223726.json","markdown":"https://secwatch.observer/filing/0001193125-24-223726.md","text":"https://secwatch.observer/filing/0001193125-24-223726.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000119312524223726/0001193125-24-223726-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000119312524223726/d861822d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:16:30.344046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5d22b96bc2","claim":"Stephen R. Davis was terminated as President and Chief Executive Officer at ACADIA PHARMACEUTICALS INC.","evidence_excerpt":"Stephen R. Davis is departing the Company and will be succeeded by Catherine Owen Adams.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070494/000119312524223726/0001193125-24-223726-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"9959f119a5","claim":"Catherine Owen Adams was appointed as Chief Executive Officer at ACADIA PHARMACEUTICALS INC.","evidence_excerpt":"On September 20, 2024, the Board appointed Catherine Owen Adams, age 54, to serve as the Chief Executive Officer of the Company, including as the “principal executive officer” of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, effective as of the Transition Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070494/000119312524223726/0001193125-24-223726-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}